Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status Prescription; Discontinued
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 42571-131; 68554-0044; 65862-932; 31722-505; 0781-5893; 0597-0123; 65162-209; 64380-709; 33342-004; 65862-027; 0378-4050; 0378-4890; 70159-002; 65862-057; 53104-7546; 65862-933; 33342-238; 64220-102; 0597-0047
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.012155%
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.0010.018233%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.030388%Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase13.03.01.031--Not Available
Alanine aminotransferase abnormal13.03.01.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Anaemia01.03.02.0010.007927%
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angina pectoris02.02.02.002; 24.04.04.0020.018233%
Angioedema10.01.05.009; 23.04.01.001--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase13.03.01.032--Not Available
Aspartate aminotransferase abnormal13.03.01.004--Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Basedow's disease05.02.02.003; 06.09.04.003; 10.04.08.004--Not Available
Blister12.01.06.002; 23.03.01.001--Not Available
Blood bilirubin13.03.01.040--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Breast enlargement21.05.04.001--Not Available
Cardiac failure congestive02.05.01.0020.030388%Not Available
Cerebrovascular accident17.08.01.007; 24.03.05.0010.036465%
Cholestasis09.01.01.0010.018233%Not Available
Chronic hepatitis B09.01.09.008; 11.05.06.005--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene